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The two subunits of core binding factor (Runx1
and CBFb) play critical roles in hematopoiesis
and are frequent targets of chromosomal trans-
locations found in leukemia. The binding of
the CBFb-smooth muscle myosin heavy chain
(SMMHC) fusion protein to Runx1 is essential
for leukemogenesis, making this a viable target
for treatment. We have developed inhibitors
with low micromolar affinity which effectively
block binding of Runx1 to CBFb. NMR-based
docking shows that these compounds bind to
CBFb at a site displaced from the binding inter-
face for Runx1, that is, these compounds func-
tion as allosteric inhibitors of this protein-
protein interaction, a potentially generalizable
approach. Treatment of the human leukemia
cell line ME-1 with these compounds shows de-
creased proliferation, indicating these are good
candidates for further development.
INTRODUCTION
The protein-protein interaction between the subunits of
the heterodimeric transcription factor CBF, core binding
factor b (CBFb), and Runx1 (CBFa) plays a critical role in
hematopoiesis (blood cell development) [1]. CBFb func-
tions to increase the DNA binding of the Runx1 subunit
20- to 40-fold [2] and to protect the Runx1 subunit against
ubiquitination and subsequent proteasome degradation
[3]. The gene coding for the CBFb subunit (CBFB) is the
target of a common chromosomal translocation, inv(16),
found in 12%–15% of acute myeloid leukemia cases [4].
This translocation results in the fusion of the N-terminal1186 Chemistry & Biology 14, 1186–1197, October 2007 ª2007165 amino acids of CBFb to the coiled-coil region of
smooth muscle myosin protein (hereafter referred to as
CBFb-SMMHC). The CBFb-SMMHC fusion protein causes
dysregulation of CBF function [5] in part by means of
anomalously tight binding to Runx1 [6]. Because binding
to Runx1 is required for the dysfunction associated with
this protein, this binding represents an excellent target
for inhibition as a potential therapeutic strategy. A small-
molecule inhibitor of this kind has the potential to be a
useful and highly specific therapeutic agent. We have de-
veloped small molecules which bind to CBFb and inhibit
Runx1 binding. This represents the first step toward our
overall goal of developing compounds which can specifi-
cally inhibit CBFb-SMMHC while minimally perturbing the
activity of CBFb itself.
Although there is a long history of development of small-
molecule inhibitors of enzymes by means of targeting their
active sites, the development of inhibitors of protein-pro-
tein interactions has been relatively limited [7–10]. Poten-
tial difficulties in developing inhibitors of protein-protein
interactions include the large surface area typically buried
at such interfaces, the lack of significant curvature on
these interfaces [7], and the increased mobility of the side
chains and often the backbone at these interfaces [11, 12].
Recent successes in the development of small-molecule
inhibitors of protein-protein interactions [7–10, 13–17]
suggest these barriers are surmountable. Mutagenesis
studies of protein interfaces have clearly demonstrated
that only a small subset of amino acids at a particular inter-
face contributes the vast majority of the binding energy.
These results clearly imply that targeting of molecules to
these so-called hot spots is highly likely to disrupt the in-
teraction and that extensive coverage of the protein inter-
face with relatively large molecules is not required. Indeed,
recent success in the development of protein-protein
inhibitors targeting Rac1 [13] and Bcl-2 [14] bodes well
for structure-based approaches to this. An intriguingElsevier Ltd All rights reserved
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hibitors [18] of protein-protein interactions in which the
molecule would bind at a site offset from the protein-pro-
tein interface and thereby not have to compete with the
binding partner. Indeed, examples of such allosteric inhib-
itors have been demonstrated for b-lactamase [19], LFA-1
[20], and nitric oxide synthase [21], suggesting this may
be a generalizable approach.
We have solved the 3D structure of CBFb using solution
NMR [22] and mapped the binding interface with Runx1 by
both chemical shift perturbation as well as Ala mutagene-
sis of the binding interface [23]. This provided the frame-
work to carry out virtual screening, and subsequent
screening by chemical shift perturbation in 2D 15N-1H
HSQC spectra of CBFb to identify potential lead com-
pounds. A FRET-based assay and an ELISA have been
developed to measure the effectiveness of these com-
pounds in inhibiting the CBFb-Runx1 Runt domain inter-
action. Using a traditional medicinal chemistry approach,
we have elaborated these compounds to identify struc-
ture-activity relationships, resulting in compounds with
significant inhibitory potency (low micromolar range). We
have used the NMR chemical shift perturbations to dock
the compounds to CBFb and show that they bind at a
site offset from the interfacial region of CBFb. These data
show that they act in an allosteric manner to inhibit the
binding of Runx1 to CBFb. These inhibitors demonstrate
activity in a cellular FRET assay in HEK293 cells and in-
hibition of proliferation of the leukemia cell line ME-1 (con-
taining the inv[16]), indicating they are good leads for
further development.
RESULTS
Lead Identification and NMR Chemical Shift
Perturbation Screening
The computer program LUDI/InsightII (Accelrys) [24, 25]
has been utilized for virtual screening using the Available
Chemicals Directory database of 70,000 commercially
available compounds with drug-like properties. The 20
conformers of CBFb used to represent the solution struc-
ture of the protein were employed for virtual screening,
which resulted in 35 compounds selected for experimen-
tal screening using NMR spectroscopy. Screening by
means of observation of chemical shift changes in the
2D 15N-1H or 13C-1H HSQC spectra of proteins in the pres-
ence of ligands has been very successfully applied [26–
29]. In this study, we have employed chemical shift pertur-
bations in the 2D 15N-1H HSQC spectra of CBFb in the
presence of ligands to identify compounds that bind to
the protein as well as to provide information on the loca-
tion of their binding site. Four of the 35 compounds
showed significant chemical shift changes in 2D 15N-1H
HSQC spectra of CBFb. Data for one of the four are shown
in Figure 1A. The structures of these four molecules (Table
1, compounds 1–4) share a common substructure, namely
a 2-aminothiazole attached to an aromatic ring. We also
titrated CBFb with each of the initial compounds to get
an estimate of the binding constant, which showed theyChemistry & Biology 14, 1186–1all bind with low millimolar dissociation constants. Be-
cause we have previously assigned the NMR spectra of
CBFb, these data also provide an indication of the binding
site on CBFb. Figure 1 shows the chemical shift perturba-
tions observed for one of the lead compounds mapped
onto the structure of CBFb. Interestingly, the observed
perturbations are consistent with binding at a site dis-
placed from the Runx1 interface (Figure 1B). Because
these lead compounds are not binding directly at the inter-
face, any inhibitory effects of these compounds would
necessarily have to occur by means of an allosteric or
noncompetitive mechanism.
FRET Assay
In order to assess the effectiveness of these compounds
in inhibiting binding of the Runx1 Runt domain to CBFb,
we have developed a FRET assay to measure this binding
(Figures 2A and 2B). We fused the green fluorescent pro-
tein derivative Cerulean to the N terminus of the Runt
Figure 1. Interactions of 2 with CBFb
(A) Selected region of the 15N-1H HSQC spectrum of CBFb (red) and
CBFb plus 2 (blue). Amides perturbed upon binding are labeled.
(B) Residues with chemical shift perturbations (red) mapped onto the
structure of CBFb (gray) complexed to the Runx1 Runt domain (green).
The side chains of N104 and I102 are shown in magenta.197, October 2007 ª2007 Elsevier Ltd All rights reserved 1187
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to the N terminus of CBFb. The ratio of the emission inten-
sities at 525 nm and 474 nm was used as the readout in
this assay. We have validated the assay by determining
the Kd for binding using serial dilution resulting in a Kd
value of 87 nM (data not shown), in very good agreement
Table 1. Results of FRET and ELISA Experiments
Compound R1 R2 R3 R4 IC50 (mM) IC50 ELISA (mM)
1 H H H H ND 27a ND
2 Me H H H ND 10a ND
3 Me H Me H ND 12a ND
4 H H CH-CH ND 9a ND
5 CF3 H H H 9.0 ± 1.4 3.0 ± 0.1
6 OMe H H H 18.5 ± 3.5 12 ± 1.4
7 OMe OMe H H 40.5 ± 4.9 18 ± 2.8
8 O-CH2-O H H 9.0 ± 1.4 6.5 ± 0.7
9 H Cl H H 12.0 ± 1.4 6.5 ± 2.1
10 H Me H H 110 ± 12 36 ± 10
11 H OMe H H 61 ± 3.0 22.5 ± 2.1
12 H OCF3 H H ND 19
a >700
13 H H Me H 5 ± 0.0 3.3 ± 0.5
14 H H Cl H 1.1 ± 0.14 0.7 ± 0.2
15 H H OMe H ND 5a >1000
16 Cl H Cl H 49 ± 15 20.5 ± 0.7
17 OMe H H Et 3.2 ± 0.3 3.5 ± 0.7
18 OMe H H Propyl 23.5 ± 1.5 3.2 ± 0.3
19 H Me H Et 66 ± 2.0 16.5 ± 4.9
20 H H OMe Et 17 ± 2.8 18 ± 4.2
21 OEt H H Et >500 >500
ND, not determined due to weak binding.
a Percent inhibition observed at 250 mM ligand concentration.
Figure 2. FRET Assay
(A) Schematic of FRET experiment.
(B) Fluorescence emission spectra (433 nm excitation) for a Cerulean-Runt domain/Venus-CBFb complex (green) and for the Cerulean-Runt domain/
Venus-CBFb complex plus a 10-fold excess of CBFb (red).
(C) Results of FRET assay for 1–4 at 250 mM ligand concentration. Error bars represent the mean ± standard deviation of two replicates.
(D) Activity (IC50) calculated from the FRET ratio (Emission525/Emission474) as a function of ligand concentration (mM) for 13.1188 Chemistry & Biology 14, 1186–1197, October 2007 ª2007 Elsevier Ltd All rights reserved
Chemistry & Biology
Allosteric Inhibitors of CBFbFigure 3. Design of Library for SAR Anal-
ysiswith the Kd value of 57 nM obtained from calorimetric
measurements of the binding of unmodified Runt domain
to unmodified CBFb [6]. The four lead compounds identi-
fied from the NMR screen were tested using this FRET as-
say at a compound concentration of 250 mM (Figure 2C).
One of the four (1) showed 30% inhibition and the re-
maining three (2–4) exhibited weak inhibition (15%) of
the interaction between the two proteins, thus validating
these compounds as potential leads for further develop-
ment. The dynamic range for the FRET assay was deter-
mined by adding a 20-fold excess of untagged CBFb to
the assay, and the associated change in the FRET ratio
was defined as 100% inhibition.
Design and Synthesis of a Compound
Library for SAR
Based on the core scaffold of compound 1, we systemat-
ically designed a targeted set of compounds to explore
the structure-activity relationships (SAR) for these inhibi-
tors. Initial efforts focused on the generation of a library
of 2-aminothiazoles to explore electronics, sterics, confor-
mation, and hydrogen bonding and resulted in the synthe-
sis and screening of over 100 compounds, resulting in 17
active compounds (Table 1). Structural information for a
select number of these compounds is illustrated in Fig-
ure 3. In general, thiazoles 4–21 were synthesized using
a modified Hantzsch thiazole reaction [30, 31] in 27%–
99% yield. Details of the syntheses are provided in Sup-
plemental Data available with this article online.
Results of NMR, FRET, and ELISA Assays
The synthesized compounds were screened by NMR and
by FRET. NMR screening was used to identify compounds
that bound to CBFb as well as the site of binding. FRETChemistry & Biology 14, 1186–119assays were then employed to assess inhibitory effective-
ness. The most frequently and most substantially per-
turbed residues in the NMR spectra are Y96, L97, K98,
A99 (b4), and G112 (b5) as well as G123 and C124 (b6),
confirming the binding of these molecules at a site dis-
placed from the heterodimerization interface (Figure 1B).
In addition, for many of the compounds, we observed
chemical shift perturbations at the heterodimerization in-
terface in the vicinity and/or at the energetic hot spots
for CBFb binding to the Runx1 Runt domain (N63, L64,
Q67, L103, N104). This suggests that despite the fact
that these compounds bind at a site displaced from the
protein-protein interface, they do affect the conformation
and/or dynamics of residues at the interface, resulting in
inhibition of the CBFb-Runx1 interaction (see Discussion
for details).
In order to obtain the more quantitative characterization
necessary to guide efforts to optimize these compounds,
we have measured the IC50 for all compounds by FRET
and ELISA assays. A representative plot from a FRET as-
say is shown in Figure 2D and inhibition data for 21 active
compounds is tabulated in Table 1. Several of these com-
pounds are very effective in inhibiting the CBFb-Runx1
interaction, five of which have IC50 values below 10 mM, in-
cluding 14 and 17 with IC50 values of 1.1 mM and 3.2 mM,
respectively. All active compounds were also tested in
the presence of detergent (0.1% Triton X-100) to exclude
the possibility of promiscuous inhibition by aggregate
(micelle) formation [32].
In order to confirm the activity of these compounds by
an independent method, we have developed an ELISA
assay to evaluate their effectiveness as well. IC50s deter-
mined by ELISA correlate very well (R = 0.91) with the
FRET data (Table 1) with no more than 3-fold differences7, October 2007 ª2007 Elsevier Ltd All rights reserved 1189
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with CBFb Calculated Using SDILICON
(A) The observed NMR chemical shift perturba-
tions (CSP) for the amide protons of the pro-
tein: cyan balls indicate positive CSP (down-
field shift) and red balls represent negative
changes (upfield shift) upon ligand binding.
The ball radius is proportional to the magnitude
of the CSP. Side chains of I102 and N104 are
shown in stick representation. The C-terminal
a helix (residues 128–135) was removed for
clarity.
(B) Side chains of CBFb residues interacting
with 10 are shown in stick representation (C,
green; O, red; N, blue; S, yellow).
(C) CBFb residues with CSP at the heterodime-
rization interface (blue). Ligand binding site and
side chains of two residues from this region
(W110 and L125) involved in intramolecular
interactions with perturbed residues from the
heterodimerization interface are in red.
(D) Side chains of CBFb residues with CSP
(blue) and their interactions with the Runt
domain (green) (amino acids involved in inter-
actions with CBFb are colored according to
atom types: C, green; O, red; N, blue).in IC50 values obtained by both methods, confirming the
reliability of the methods we applied for inhibition mea-
surement. The only exceptions are compounds 18 and
19, which had IC50 values 7.5-fold and 4-fold lower, re-
spectively, when measured by ELISA versus FRET.
NMR-Based Docking of Ligands
CBFb has not been successfully crystallized as of yet as
a single protein, so we obtained data from NMR chemical
shift perturbation studies to determine the binding mode
for the inhibitors on CBFb. We have used the approach
previously described by McCoy and Wyss [33, 34] and im-
plemented in the SDILICON program (http://tonga.usip.
edu/gmoyna/sdilicon/sdilicon.c/). NMR chemical shift
perturbations (CSP) for two compounds (10 and 8), se-
lected based on their favorable solubility properties at high
concentrations, were used to guide the docking to CBFb.
The LigandFit/Cerius2 program was used first to find initial
ligand ‘‘poses’’ in the protein binding site, followed by
SDILICON calculations to further optimize ligand orienta-
tion and conformation. Out of seven poses for 10, two of
them (indicated as clusters 2 and 4 in Table S1) clearly
showed the best agreement between calculated and
experimental CSP values. The values calculated by
SDILICON (final shift deviation and shift penalty energy
contribution) were better for binding mode 2, suggesting
this binding mode as the most probable orientation of 10
in the binding site. Nevertheless, both orientations were
selected for further analysis to identify the correct ligand
binding mode. These binding modes differ only in their re-
versed orientation in the binding site (Figure S1). The same
result was obtained for 8, where five starting ligand orien-
tations were used as input for the CSP calculations, and
two with the lowest energy showed the best agreement
between calculated and measured CSP values. In both1190 Chemistry & Biology 14, 1186–1197, October 2007 ª2007binding modes, 8 occupies the same area of the binding
site as 10, and these binding modes superimpose very
well with the two most probable orientations of 10 in the
CBFb binding site. The same binding modes obtained as
a result of calculations for two different CBFb ligands
strongly suggests that the core pharmacophore, that is,
the phenyl and thiazole rings, occupies the same site for
all the ligands derived from this core. This assumption is
strongly supported by the observation of NMR chemical
shift perturbations for amino acids in this binding site for
all of the ligands with this core scaffold. In order to distin-
guish between the two proposed binding modes, the po-
tential interactions of all ligands with CBFb were analyzed
based on the positions of the ‘‘core’’ fragments taken from
binding mode 2 and binding mode 4 of 10. Ligands were
examined for potential steric conflicts as well as affinity
differences to distinguish between the two modes. This
analysis is clearly only consistent with binding mode 2
(Figures 4A and 4B). This is in good agreement with the
CSP calculations, which showed much lower differences
between the calculated and measured values for this
binding mode (correlation coefficient: R = 0.95; see Fig-
ure S2). In addition, positive CSP values are observed for
all amide protons which are in the plane of these aromatic
rings, whereas negative values are observed for the amide
protons above the plane (Figure 4A), again consistent with
this binding mode. All these findings make ligand binding
mode 2 (Figures 4A and 4B) very reliable and make possi-
ble further analysis of ligand-protein interactions based on
this binding mode.
The binding site on CBFb for these compounds employs
the residues of the loop connecting b3 with b4 and three
b strands: b4, b5, and b6 (Figures 4A and 4B), and is local-
ized on the protein surface. This protein cleft is not in-
volved in the binding of CBFb to the Runt domain, asElsevier Ltd All rights reserved
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(A) Activity of compounds in the in vivo FACS/FRET assay. Compounds were added to Venus-CBFb (V-CBFb)- and Cerulean-Runt domain (C-RD)-
expressing cells at 25 mM and 100 mM concentrations, while all controls were treated with 1% DMSO for 5 hr. C-RD + V-CBFb represents HEK293
cells expressing Venus-CBFb and Cerulean-Runt and was defined as a 100% FRET signal. C-RD + V-CBFb + CBFb refers to cells expressing Venus-
CBFb, Cerulean-Runt, and CBFb and was defined as 50% FRET. C-RD + V-CBFbmut refers to cells expressing Venus-CBFb G61A/N104A and
Cerulean-Runt and was defined as 0% FRET. Bars represent mean percent FRET values ± 95% confidence intervals based on a regression line
derived from positive and negative control values. All treatments and negative controls were statistically significant (p < 0.001) in comparison with
the C-RD + V-CBFb control in an unpaired, two-tailed t test. The graph represents combined data from three independent experiments, with triplicate
to quintuplicate samples per treatment in each experiment.
(B) Effect of compounds on proliferation of ME-1 cells measured after 72 hr using an MTT assay. Absorbance measured at 570 nm for cells treated
with 0.25% DMSO was defined as 100% proliferation (0.25% DMSO had no effect on growth) and all data were normalized with respect to this. The
graph represents mean values and standard deviations for combined data from two independent experiments, each performed in quadruplicate.
Staurosporine (SS) was used as a positive control for inhibition of proliferation.
(C) Results of an ELISA for Runx1 DNA binding in HL60 nuclear extracts after treatment with 17. Each experiment was repeated five times and data
shown are the mean ± SD.mentioned above. The bottom of the binding site is formed
by the backbone atoms of the residues originating from
these strands, with the amino acids of b4 (Y96, L97,
K98) and b5 (K111, G112) being in closest proximity to
the ligand (Figures 4A and 4B). The majority of the interac-
tions between the protein and the ligand involve the side
chains of various CBFb residues. The side chains of K98
and K111 on one side and Y96 and R90 from the other
side define the shape and spatial arrangement of the bind-
ing cavity, which remains open to the solvent (Figure 4B).
The thiazole ring interacts with the hydrophobic portion
of the K111 side chain. A hydrogen bond is expected be-
tween the carboxyl group of E126 and the amino group at-
tached to the thiazole ring. The phenyl ring of the ligand is
inserted between the side chains of K98 and Y96, both be-
ing involved in hydrophobic interactions with this ring. In
addition, the guanidine group of Arg90 is in proximity to
both aromatic rings of 10, particularly the phenyl ring (dis-
tance <4 A˚), making it possible for p-cation interactions
between these groups. The methyl group at the meta posi-
tion of the phenyl ring in 10 is directed at the backbone of
L97 (Figure 4B) and is surrounded by the backbone atoms
of the residues 96–98. The meta-methyl group is involved
in hydrophobic interactions with the K98 and Y96 side
chains.
FACS/FRET Analysis of Inhibition in HEK293 Cells
In order to test the cell permeability of these compounds
as well as their ability to disrupt the CBFb-Runx1 interac-
tion in mammalian cells, we utilized a fluorescence-acti-
vated cell sorting-fluorescence resonance energy transfer
(FACS/FRET) method [35–37]. FACS/FRET provides
the advantages of high-throughput screening of cellsChemistry & Biology 14, 1186–1with specific levels of expression of fluorescent proteins
while avoiding drawbacks common to FRET microscopy
methods such as photobleaching and the effects of trans-
fection efficiency. Although FACS/FRET has been suc-
cessfully used previously to assess extra- and intracellular
protein-protein interactions [36, 38–41], this is, to our
knowledge, its first application for screening compounds
which disrupt protein-protein interactions. We performed
the screen on suspension human embryonic kidney 293
(HEK293) cells which were transiently transfected with
plasmids expressing Cerulean-Runt and Venus-CBFb, or
the negative control Venus-CBFb G61A/N104A mutant,
which has more than 100-fold lower affinity for the Runt
domain [6, 23]. Alternatively, cells were transfected with
Cerulean-Runt-, Venus-CBFb-, and CBFb-coding plas-
mids, the last as an approximately 50% competition con-
trol. Two days posttransfection, cells were incubated with
compounds at 25 or 100 mM concentrations or 1% DMSO
vehicle as control for 5 hr to allow for energy-dependent
or -independent uptake. We measured FRET output from
cells expressing equivalent uniform levels of Venus-CBFb,
as Cerulean emission may fluctuate upon disruption of
Runt and CBFb interaction. The three tested compounds
decreased FRET emission in a concentration-dependent
manner with high statistical significance (see Figure 5A).
At the 100 mM concentration, the FRET signal was
52.7% ± 7.1, 57.8% ± 4.9, and 79.7% ± 4.5 of control for
compounds 17, 14, and 13, respectively. Compound 17
displayed the highest activity, and its inhibition of the
Runt domain-CBFb interaction was quite comparable to
the decrease observed in the CBFb competition control.
Importantly, we saw no evidence of toxicity to the cells
upon compound treatment.197, October 2007 ª2007 Elsevier Ltd All rights reserved 1191
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Mammalian Cell Lines
In order to probe the potential efficacy of the compounds
for inv(16) leukemia, we have tested their ability to inhibit
proliferation of ME-1 cells, a leukemia cell line expressing
CBFb-SMMHC, product of the inv(16). ME-1 [42, 43] cells
were treated with a single dose of compound at various
concentrations (0, 25, 50, 100 mM) and assayed for inhibi-
tion of proliferation by MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) assay 72 hr after treat-
ment. As seen in Figure 5B, compound 17 was most active
in this assay, showing a clear dose-dependent reduction
in proliferation. More modest effects were seen with 13
and 14, consistent with the FACS/FRET results in HEK293
cells, where 17 was also the most potent. As all three com-
pounds have similar IC50 values (Table 1), this suggests
there may be differences in uptake or serum absorption
among these three inhibitors.
Based on the block in proliferation of ME-1 cells seen
with 17, we sought to assess whether there is increased
differentiation of ME-1 cells upon treatment with 17. As
surface markers for the differentiation of ME-1 cells are
not well established, we have used changes in morphol-
ogy to qualitatively assess the extent of differentiation
[44]. Figure 6 shows the results of this analysis. Treatment
with 17 for a 3 day period showed an increase in apoptotic
cells but limited if any effects on the morphology of living
cells (see Figures 6D–6F). In contrast, a 14 day treatment
with 17 or 17 plus all-trans-retinoic acid (ATRA) (see Fig-
ures 6G–6I) resulted in cells with greater variation in size
and shape, lower nuclear-to-cytoplasmic ratio, increased
folding and lobation of nuclei, and more clumped chroma-
tin. All of these morphology changes are consistent with
differentiation to more mature forms.
In order to assess the general cytotoxicity of 17, we
have assayed it against several cell lines other than ME-1.
Hep-G2 and HK-2 cells, derived from liver and kidney, two
of the most frequent sites of toxicity in vivo, were evalu-
ated. As seen in Figure S4, at 50 mM, 17 actually increases
proliferation of Hep-G2 cells (+20%), whereas HK-2 cells
are inhibited (31%) to a similar extent as the ME-1 cells
(see Figure 5). In addition, we have treated three leukemia
cell lines (K562, HL60, U937) with 17 and assessed the
impact on proliferation. Whereas K562 cells were not
affected to any significant extent (10%), the HL60
(33%) and U937 (42%) were affected to a similar extent
as seen for ME-1 cells. The increased effect in HL60 and
U937 cells versus K562 cells is consistent with the higher
levels of Runx in HL60 and U937 and therefore potentially
higher dependence on Runx function for proliferation. This
inhibitor is clearly not pan-cytotoxic, making it a viable
candidate for further development.
Effect of Compounds on DNA Binding by Runx1
As it is known that CBFb enhances the DNA binding of
Runx proteins [2], treatment with CBFb inhibitors should
reduce DNA binding by Runx in a cellular context. In order
to test this, we have tested the effect of 17 on Runx1 DNA
binding in an HL-60 nuclear extract using a Runx1 ELISA1192 Chemistry & Biology 14, 1186–1197, October 2007 ª2007assay (Active Motif). As seen in Figure 5C, there is indeed
a statistically significant reduction in Runx1 bound to DNA
upon treatment with 17.
DISCUSSION
Allosteric Inhibition of the CBFb-Runx1
Interaction
The compounds generated by virtual screening and
selected for experimental evaluation were originally ex-
pected to interact with CBFb at the heterodimerization in-
terface. However, we have shown by NMR spectroscopy
that they bind to a novel allosteric site on CBFb. The lack
of significant curvature at the heterodimerization interface
of CBFb likely makes it difficult to design compounds
which can bind there effectively. The allosteric site on
CBFb is well defined in terms of shape and amenable to
binding small molecules. In fact, as a result of further
virtual screening and experimental screening searches
carried out to date, we have identified three additional
classes of small-molecule inhibitors interacting with this
allosteric site and blocking heterodimerization of CBFb
(data not shown). Despite extensive effort, we have not
been able to identify a small-molecule inhibitor interacting
with CBFb at the heterodimerization interface. This is likely
to be an issue that arises for other protein-protein interac-
tion inhibitors. Our successful identification of a targetable
allosteric site on CBFb presents a potentially generalizable
approach to circumvent this problem.
Structure-Activity Analysis of IC50 Data
Using the calculated binding mode of 8 and 10 to CBFb, we
have analyzed the interactions of other inhibitors (Table 1)
to gain insight into the structure-activity relations for these
compounds and guide further optimization. According to
this binding mode, a relatively large substituent can be
introduced at position 5 of the thiazole ring, as there is an
appropriate cleft in the protein binding site able to accom-
modate such a substituent. In addition, our analysis pre-
dicts that smaller functional groups can be attached at
the meta and para positions of the phenyl ring, whereas
only a small substituent can fit into the area at the ortho
position. The FRET and ELISA data strongly support
this binding model. In general, ortho substitutions were
more active for both electron-donating and -withdrawing
groups. At the ortho and meta positions, electron-with-
drawing groups generally resulted in increased efficacy
relative to electron-donating groups. The SAR analysis
presented below is based on the FRET data, but a very
similar trend is observed for the ELISA results.
The largest improvements in IC50 were observed for li-
gands bearing small substituents at the ortho position of
the phenyl ring. The incorporation of the chloro (14) and
methyl (13) groups, which are similar in radius, at this
position increases the ligand affinity about three orders
of magnitude (IC50 = 1.1 mM and 5 mM, respectively) com-
pared to the original compounds 1–4 (IC50 > 1 mM). Based
on the calculated binding mode, substituents introduced
at the ortho position approach residues 96–98 from b4Elsevier Ltd All rights reserved
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All cells were stained with Wright-Giemsa stain.
(A and B) Blast-like morphology of the ME-1 cell line seen after 3 and 14 days of treatment with the 0.25% DMSO control. Cells are uniformly large,
oval, have high nuclear-cytoplasmic ratios, and a fine chromatin pattern.
(C) Apoptotic cells observed after a 3 day treatment with the protein kinase C inhibitor staurosporine.
(D–F) Similar blast-like morphology and increased apoptosis seen after 3 days of treatment with 17 at 25 mM (D) and 50 mM (E and F).
(G–I) Effects of a 14 day treatment with 17 in inducing morphologic changes of differentiation to more mature forms with variation in cell size and
shape, lower nuclear-to-cytoplasmic ratio, folding and lobation of nuclei, and more clumped chromatin at 25 mM (G), 50 mM (H), and 25 mM in
combination with 1 mM all-trans-retinoic acid (ATRA) (I).and 111–112 from b5 (Figures 4A and 4B). The low IC50
values observed for these compounds can be explained
by means of favorable hydrophobic interactions with the
side chains of K111 and K98. A methoxy substituent at
the ortho position (15) almost abolishes inhibition, as a
result of the size and electrostatic repulsion between the
oxygen atom of the methoxy group and the carbonyl oxy-
gen of L97 (distance 3 A˚). Substituents at the meta posi-
tion of the phenyl ring are directed toward residues in b4
(compounds 9, 10; Figure 4). Larger substituents (11, 12)
are directed at residues in b4 as well as the loop preceding
b4 (residues 84–87). The chloro group has proven best atChemistry & Biology 14, 1186–1this position, resulting in an IC50 value of 12 mM for 9. Re-
placement of chloro with methyl (10) or methoxy (11)
increases the IC50 by 9-fold and 5-fold (interactions of
10 with CBFb are described in detail above).
No activity was observed for the compounds with larger
substituents at the meta position (e.g., ethyl, dimethyl-
amine group), as they cannot be accommodated in this
area of the binding site. The incorporation of the trifluoro-
methyl (5) and methoxy (6) groups at the para position of
the phenyl ring increases the ligand affinity significantly
(IC50 = 9 mM and 18.5 mM, respectively) compared to
the parent compounds 1 and 2. The para substituents197, October 2007 ª2007 Elsevier Ltd All rights reserved 1193
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cavity is formed by E84, Y85, V86, and D87. A chloro sub-
stituent at the para position resulted in an inactive com-
pound (data not shown), consistent with the reduced ac-
tivity of 16 versus 14. Larger substituents (e.g., ethoxy)
cannot be accommodated in this area of the binding site
(data not shown). Simultaneous substitution at para and
meta positions by methoxy groups (7) reduces inhibition
by 2-fold compared to single methoxy substitutions (com-
pounds 6 and 11), indicating that at least a part of the bind-
ing site is shared between the two groups so they cannot
be well accommodated simultaneously. This is consistent
with the improved activity of 8 versus 7. Compound 8 con-
tains a benzo[d] [1, 3]dioxole ring system at the corre-
sponding positions, which makes it smaller, more rigid,
and more appropriate to fit and interact with this region
of the binding site.
We have also substituted at the 5 position of the thiazole
ring. Incorporation of an ethyl group at this position proved
to be the most effective, with an up to two orders of mag-
nitude decrease in the IC50 value (compare 20 with 15).
The same substitution resulted in a 6-fold increase in po-
tency for 17, yielding a low micromolar ligand (IC50 = 3.2
mM), and a 2-fold enhancement of the binding affinity for
19 compared to the parent compounds lacking the ethyl
group at the thiazole ring (6 and 10, respectively). A propyl
group proved to be a less effective substituent at this
position (18, IC50 = 23.5 mM), with no improvement in the
binding affinity versus parent compound 6. The orientation
of the ligand thiazole ring in the CBFb binding site causes
the substituent at the 5 position of the thiazole ring to be
positioned parallel to the backbone of the residues in
b5, with G112 in closest proximity. The ethyl and propyl
groups are inserted between the side chains of K111
and Y96, with both engaged in hydrophobic contacts with
these substituents. The propyl group is partially solvent
exposed, which may make it less effective than an ethyl
at this position.
Structural Basis for Inhibition
According to the 15N-1H HSQC spectra of CBFb, these
compounds bind to an allosteric site displaced from the
heterodimerization interface. However, for many of the
compounds, we also observed perturbations of the chem-
ical shifts for at least one of the CBFb residues localized at
the heterodimerization interface or in the vicinity thereof
(Figures 4C and 4D). These residues can be categorized
into two groups: amino acids located in b3 (N63, L64,
Q67) and residues belonging to a loop connecting b4
with b5 (L103, N104, G105). All of these residues at the het-
erodimerization interface are located 10 A˚ or more from the
ligand in our docked model, and thus it is not possible that
ring current effects from the ligand could be causing these
changes. Rather, the changes observed for these residues
must arise indirectly from alteration of the conformation or
dynamics of these residues as a result of ligand binding.
The backbone of Q67 is 4.5 A˚ away from the backbone
of b4 residues A99 and K98, both of which are in direct
contact with the allosteric ligands (Figure 4A). The proxim-1194 Chemistry & Biology 14, 1186–1197, October 2007 ª2007ity of Q67 to b4 likely results in an altered conformation for
this residue upon ligand binding, consistent with the ob-
served chemical shift perturbations seen with ligand bind-
ing. Structures of Runt domain-CBFb complexes show
that the side chain of Q67 is directly involved in interac-
tions with Runt domain residues P157, N155, and F153
(Figure 4D). The energetic importance of these interac-
tions has been demonstrated with a Q67A mutation de-
creasing Runt domain binding to CBFb 10-fold [23].
Therefore, conformational changes of Q67 induced by li-
gand binding may contribute to inhibition. Chemical shift
changes were also observed for L64, located in the middle
of b3 at the heterodimerization interface (Figure 4C). L64
is involved in intramolecular hydrophobic interactions
with the side chains of W110 and L125, both of which
are adjacent to the ligand binding site. The side chain of
W110 is positioned close (4–5 A˚) to the backbone of b5
(G112 and K113) and b6 residues (G123 and C124), which
are also perturbed upon ligand binding. Conformational
changes of the W110 and L125 side chains may be in-
duced by ligand binding and propagated to L64 and L103
(the latter is involved in the same hydrophobic core; see
Figure 4C). The side chain of L64 is involved in a hydropho-
bic interaction with Runx1 residues V159 and T149 in the
complex and an L64A mutation also affects heterodimeri-
zation [23]. Again here, induced conformational changes
of L64 could affect these interactions, resulting in inhibi-
tion of CBFb heterodimerization.
Two of the perturbed residues located in the loop con-
necting b4 with b5, L103 and N104, have been identified
as energetic ‘‘hot spots’’ on CBFb binding to Runx1 [23].
These residues are in proximity to b4 residues 96–99,
which are in direct contact with our allosteric ligands. In
addition, L103 is part of the hydrophobic core involving
W110, L125, and L64, which is affected by ligand binding
(see above). Therefore, the binding of ligands to the allo-
steric site could easily alter the conformation and/or dy-
namics of this critical part of the protein (b4-b5 loop),
thereby inhibiting binding of the Runx1 Runt domain to
CBFb. L103 forms hydrophobic interactions with the Runt
domain residues V159 and T161 (Figure 4D) in the com-
plex, and an L103A substitution decreases binding 5-
fold [23]. N104 is involved in a hydrogen-bond network
with the backbone and side chain of T161 and the back-
bone of V159 in the Runt domain. The importance of
N104 for binding to Runx1 (an N104A substitution de-
creases binding 50-fold [23]) strongly suggests that
alteration of the conformation of this residue contributes
to inhibition.
Our results are consistent with a model where the com-
pounds induce changes in local conformation and/or dy-
namics which are transmitted through the protein to resi-
dues at the CBFb-Runt domain interface, resulting in an
altered interface which can no longer bind as effectively.
This is similar to observations in other allosterically regu-
lated proteins, where binding to allosteric sites causes
conformational and/or dynamic changes at a separate
functional site on the protein, resulting in altered affinity
[45, 46].Elsevier Ltd All rights reserved
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We have shown by analysis of changes in morphology that
our CBFb inhibitors can induce increased differentiation
in ME-1 cells as well as an increase in apoptosis, explain-
ing the decrease in proliferation observed. Multiple mech-
anisms for these effects are possible, including release
of Runx from a nonproductive Runx/CBFb-SMMHC com-
plex, decreased Runx binding to DNA as a result of re-
duced CBFb binding (see Figure 5C), or alteration of the
components present in the multiprotein Runx-DNA com-
plex as a result of reduced CBFb and/or CBFb-SMMHC
binding. Because the level of functional Runx present in
cells has been shown to be critical for cell-cycle progres-
sion [47], any or all of these could have a substantial
impact on proliferation.
SIGNIFICANCE
Numerous inhibitors of enzymatic activity have been
developed; however, the development of inhibitors of
protein-protein interactions has only recently come
to the forefront as a viable approach. Allosteric inhibi-
tion of such protein-protein interactions presents a
number of advantages, including not having to com-
pete for binding with the partner protein, however to
date there are very few examples of such inhibitors.
We have developed allosteric small-molecule inhibi-
tors of the binding of Runx1 to CBFb. To our knowl-
edge, these compounds represent the first small-mol-
ecule inhibitors of the protein-protein interaction
between Runx1 and CBFb. These compounds inhibit
the proliferation of the human leukemia cell line ME-
1, making them excellent candidates for further devel-
opment. Our results clearly provide validation for
development of allosteric inhibitors of protein-protein
interactions as a powerful approach for achieving inhi-
bition of these interactions.
EXPERIMENTAL PROCEDURES
Chemical Synthesis
Descriptions of the chemical syntheses are provided in the Supple-
mental Data.
NMR Spectroscopy
A description of the NMR spectroscopy is provided in the Supplemen-
tal Data.
FRET Assays
The His6 tag and Cerulean were inserted into the pET22b vector
(Novagen, Madison, WI, USA) between the NdeI and BamHI restriction
sites, and the Runx1 Runt domain (Runx1 41–190) was inserted be-
tween the BamHI and XhoI sites to create the Cerulean-Runt domain
fusion protein. A two amino acid linker (Gly-Ser) was included between
Cerulean and Runx1. The His6 tag and Venus were inserted into the
pET22b vector (Novagen) between the NdeI and BamHI restriction
sites, followed by CBFb (1–141) inserted between the BamHI and
XhoI sites to create the Venus-CBFb fusion protein. A Gly-Ser linker
was also included between Venus and CBFb. The fusion proteins
were purified by standard Ni-affinity chromatography. For the FRET
measurements, the Cerulean-Runt and Venus-CBFb fusion proteins
were dialyzed into FRET assay buffer (25 mM Tris-HCl [pH 7.5], 150Chemistry & Biology 14, 1186–11mM KCl, 2 mM MgCl2). Protein concentrations were determined by
UV absorption at 433 nm for Cerulean-Runt and 513 nm for Venus-
CBFb (3 = 34,000 M1cm1 and 92,200 M1cm1, respectively). Equal
molar concentrations of the two proteins were mixed together, diluted
to 150 nM with FRET assay buffer containing 0.1% BSA, and incu-
bated for 1 hr. A 190 ml aliquot of the protein mixture and 10 ml of
a DMSO solution of the compounds were mixed on 96-well black
COSTAR (Corning Life Sciences, Lowell, MA, USA) plates and incu-
bated at room temperature for 1 hr. A PHERAstar microplate reader
(BMG Labtech, Durham, NC, USA) was used to measure fluorescence
(excitation at 433 nm and emission measured at 474 and 525 nm). For
IC50 determinations, the ratios of the fluorescence intensities at 525
nm and 474 nm were plotted versus the log of compound concentra-
tion, and the resulting curve was fit to a sigmoidal curve using Origin
7.0 (MicroCal, Northampton, MA, USA). Mean values of IC50 originat-
ing from two independent measurements performed in duplicate to-
gether with the standard deviations are reported.
ELISA Assay
A description of the ELISA for the Runt domain-CBFb interaction is
provided in the Supplemental Data.
NMR-Based Docking
A description of the NMR-based docking is provided in the Supple-
mental Data.
Analysis of Compound Inhibition in HEK293
Cells by FACS/FRET
A description of the FACS/FRET protocol is provided in the Supple-
mental Data including Figure S3.
MTT Assay of Compound Effects on Proliferation
of ME-1 Cells
ME-1 cells were kindly provided by Dr. Paul Liu (NIH, Bethesda, MD,
USA). ME-1 cells were grown in RPMI 1640 with Glutamax, 20%
heat-inactivated fetal bovine serum, and 1% penicillin/streptomycin
(Invitrogen, Carlsbad, CA, USA). The cells were plated in 90 ml in 96-
well flat bottom microtiter plates (Fisher Scientific, Newark, DE, USA)
at a concentration of 43 105/ml and treated with 0.25% sterile DMSO
(Sigma, St. Louis, MO, USA), 1 mM staurosporine (Sigma), or serial
dilutions of compounds from 40 mM stock solutions in DMSO. Cells
were incubated in a 5% CO2 incubator at 37
 for 72 hr. A Vybrant
MTT cell proliferation assay kit (Molecular Probes, Eugene, OR, USA)
was used with addition of 10 ml of 12 mM MTT solution to each well fol-
lowed by incubation at 37C for an additional 4 hr. One hundred micro-
liters of sodium dodecyl sulfate in 0.01 M HCl was added to each well
and incubated at 37C overnight. Plates were read for absorbance
at 570 nm using a PHERAstar BMG microplate reader. Mean values
and standard deviations were determined from two independent
experiments, each performed in quadruplicate, for each condition.
Runx1 ELISA for DNA Binding
An ELISA was run using an AML-1/Runx1 transcription factor assay kit
purchased from Active Motif (Carlsbad, CA, USA) using the manufac-
turer’s protocol in order to determine DNA binding by measurement of
UV absorbance at 450 nm. Five micrograms of HL60 nuclear extract
from Active Motif was added to each with the exception of the negative
control, which contained only nuclear extract and binding buffers. One
hundred percent DMSO and 40 mM 17 in DMSO were diluted in nu-
clear extract buffer and added to attain final concentrations of 0.25%
DMSO and 100 mM 17 in 0.25% DMSO. The mixtures were incubated
for 1 hr at room temperature. Each condition was repeated five times.
Supplemental Data
Supplemental Data include four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
http://www.chembiol.com/cgi/content/full/14/10/1186/DC1/. Table
S1 and Figures S1 and S2 show results of NMR CSP-based docking97, October 2007 ª2007 Elsevier Ltd All rights reserved 1195
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Allosteric Inhibitors of CBFbfor compound 10. A description of the procedure employed for FACS/
FRET in HEK293 cells is provided in Figure S3. Descriptions of the
ELISA assay and the testing of 17 against the Hep-G2, HK-2, K562,
HL60, and U937 cell lines (Figure S4) are provided. Descriptions of
the synthesis and characterization for all compounds are provided.
The Protein Data Bank format coordinates for 10 docked to CBFb
are also provided.
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